Blog - INTERNET MÉDICA

Fibrinogênio Plasmático Online (Serum Fibrinogen)

Por Paulo Leite 20/09/2019

¨O fibrinogênio é uma proteína inflamatória de fase aguda, responsável por funções ímpares na cascata de coagulação, sua associação com fenômenos trombóticos e inflamatórios já foi extensamente estudada. Dentre elas, a associação com o infarto do miocárdio é, sem dúvida, a mais amplamente avaliada. Altos níveis de fibrinogênio podem contribuir para doenças vasculares através do aumento da viscosidade sanguínea, do estímulo à formação de fibrina, ou do aumento da interação plaqueta-plaqueta. O fibrinogênio atua através da ligação ao receptor plaquetário glicoprotéico IIb IIIa, exposto na superfície da plaqueta quando esta se encontra ativada. Dessa forma, ele proporciona a agregação entre duas ou mais células e a formação do trombo plaquetário. Além disso, o fibrinogênio também possui um papel fundamental no estágio final da cascata de coagulação, quando da elaboração da rede de fibrina, formando monômeros de fibrina ao ser clivado pela trombina (outro importante ativador plaquetário), formada a partir da ativação do fator X, que, por sua vez, se origina da ativação do fator tecidual. Níveis elevados de fibrinogênio plasmático têm sido associados à progressão tumoral em várias neoplasias. Um recente estudo mostrou que o fibrinogênio plasmático está associado a aterosclerose subclínica em indivíduo com excesso de peso. Em um estudo chinês, publicado em 2019, o fibrinogênio mostrou estar associado à mortalidade por todas as causas em 2 anos em pacientes que recebem intervenção percutânea coronária. Um estudo mostrou que é provável que o fibrinogênio seja um biomarcador útil para estratificar indivíduos com DPOC naqueles com alto ou baixo risco de exacerbações futuras e pode identificar aqueles com maior risco de mortalidade. A redução acentuada do fibrinogênio plasmático ocorre nas coagulopatias por consumo, fibrinólise e disfibrogenemias. Os valores de referência para fibrinogênio são de 200 a 400 mg/dL¨

■ Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous intervention: a large single-center study

Ping Jiang, Zhan Gao, Wei Zhao et al

Chin Med J (Engl) 2019 Apr 20; 132(8): 914–921

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595753/

■ Elevated baseline serum fibrinogen: effect on 2-year adverse cardiovascular events following percutaneous coronary intervention

Lawrence Ang, Omid Behnamfar, Samhita Palakodeti et al

J Am Heart Assoc. 2017 Nov; 6(11): e006580.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721757/

■ Fibrinogen concentrations predict long-term cognitive outcome in young ischemic stroke patients

Annie Pedersen, Tara M. Stanne, Petra Redfors, Jo Viken, Hans Samuelsson, Staffan Nilsson, Katarina Jood, Christina Jern

Res Pract Thromb Haemost. 2018 Apr; 2(2): 339–346

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055490/

■ Identification and characterization of novel mutations implicated in congential fibrinogen disorders

Natalie Smith, Larissa Bornikova, Leila Noetzli, et al

Res Pract Thromb Haemost. 2018 Oct; 2(4): 800–811

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178649/

■ Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics

Mark A. Petersen, Jae Kyu Ryu, Katerina Akassoglou

Nat Rev Neurosci. 2018 May; 19(5): 283–30

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743980/

■ Human fibrinogen: molecular and genetic aspects of congenital disorders

Giovanni Luca Tiscia, Maurizio Margaglione

Int J Mol Sci. 2018 Jun; 19(6): 1597

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032319/

■ Clinical consequences and molecular bases of low fibrinogen level

Marguerite Neerman-Arbez, Alessandro Casini

Int J Mol Sci. 2018 Jan; 19(1): 19

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796141/

■ Fibrinogen and clot-related phenotypes determined by fibrinogen polymorphisms: independent and IL-6-interactive associations

Toinét Cronjé, Cornelie Nienaber-Rousseau, Lizelle Zandberg et al

PLoS One. 2017; 12(11): e0187712

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669433/

■ Fibrin formation, structure and properties

J W Weisel, R I Litvinov

Subcell Biochem 2017: 82: 405-456

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536120/

■ Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic cirrhotic patients

E G Giannini, E Giambruno, M Brunacci et al

Annals of Hepatology 2018, vol 17 (5)

https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-low-fibrinogen-levels-are-associated-S1665268119302625

■ Prognostic value of plasma fibrinogen in hepatocellular carcinoma: a meta-analysis

G Huang, H Jiang, Y Lin et al

Cancer Management and Research 2018, vol 10: 5027-5041

https://www.dovepress.com/prognostic-value-of-plasma-fibrinogen-in-hepatocellular-carcinoma-a-me-peer-reviewed-fulltext-article-CMAR

■ Evaluation of serum D-dimer, fibrinogen, and CA 19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma

J Cao, Z Fu, L Gao et al

World Jounral of Surgical Oncology 2017, col 15, article number: 48

https://wjso.biomedcentral.com/articles/10.1186/s12957-017-1104-9

■ Fibrinogênio e Aterosclerose

Cerit, Levent and Menti, Eduardo

Arq. Bras. Cardiol., Feb 2017, vol.108, no.2, p.189-190

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2017000200189&lng=pt&nrm=iso&tlng=pt (Portuguese)

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2017000200189&lng=en&nrm=iso (English)

■ Serum fibrinogen levels are positively correlates with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study

Xuefeng Yu, Fulan Hu, Qiang Yao et al

BMC Cancer. 2016; 16: 48

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946212/

■ Preoperative serum fibrinogen is an independent prognostic factor in operable esophageal cancer

Shui-Shen Zhang, Yi-Yan Lei, Xiao-Li Cai et a

Oncotarget. 2016 May 3; 7(18): 25461–2546

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041917/

■ Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease

Annelyse Duvoix, Jenny Dickens, Imran Haq et al

Thorax. 2013 Jul; 68(7): 670–676

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711372/

■ Elevated fibrinogen plasma level is not an independent predictor of poor prognosis in a large cohort of Western patients undergoing surgery for colorectal cancer

Corrado Pedrazzani, Guido Mantovani, Gian Luca Salvagno et al

World J Gastroenterol. 2016 Dec 7; 22(45): 9994–10001

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143766/

■ Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients

Xiang Zhang, Qiang Long

Medicine (Baltimore) 2017 Apr; 96(17): e669

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413237/

■ Prognostic significance of pretreatment plasma fibrinogen in patients with hepatocellular and pancreatic carcinomas: a meta-analysis

Rui Ji, Qian Ren, Suyang Bai, Yuping Wang, Yongning Zhou

Medicine (Baltimore) 2018 Jun; 97(25): e10824

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023750/

■ Short-term recovery patterns of plasma fibrinogen after cardiac surgery: a prospective observational study

Gabor Erdoes, Wulf Dietrich, Monika Pia Stucki et al

PLoS One. 2018; 13(8): e0201647

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075772/

■ Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk

Katherine Kearney, Darren Tomlinson, Kerrie Smith, Ramzi Ajjan

Cardiovasc Diabetol. 2017; 16: 34

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345237/

■ Serum fibrinogen level in type 2 diabetes mellitus

S Dhawale, S Jayant, A K Gupta

International Journal of Advanced Medicine 2016, vol 3 (1)

https://www.ijmedicine.com/index.php/ijam/article/view/235/217

■ High sensitivity C reactive protein, fibrinogen levels and the onset of major depressive disorder in post-acute coronary syndrome

Marianne Lafitte, Sandrine Tastet, Paul Perez et al

BMC Cardiovasc Disord. 2015; 15: 23

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436867/

■ Role of serum fibrinogen levels in patients with rotator cuff tears

U G Longo, S Petrillo, A Berton et al

International Journal of Endocrinology 2014, Article ID 685820, 5 page

https://www.hindawi.com/journals/ije/2014/685820/

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601

Tel: 33245518 (Consulta Particular/Unimed)

– Centro Médico Unimed BH/Contagem/Pedro I

Belo Horizonte/MG/Brasil

CRMMG: 7026

Email: pfleite1873@gmail.com

Hemofilia Online (Hemophilia)

Por Paulo Leite 19/09/2019

¨Hemofilias são doenças hematológicas que acarretam alterações no processo da coagulação, devido à deficiência de algum fator de coagulação. As causas da doença são genéticas e as hemofilias mais comuns são a hemofilia A (deficiência de fator VIII) e hemofilia B (deficiência de fator IX). O gênero masculino é o mais acometido, com pico de ocorrência entre 20 e 29 anos, sendo que o tipo A aparece com maior frequência. Em todo mundo, 6,9 milhões de pessoas apresentam algum distúrbio hemorrágico e, no Brasil, quase 11 mil pessoas possuíam diagnóstico de algum tipo de hemofilia em 2012. Em virtude das alterações do processo de coagulação, as hemorragias tornam-se as complicações mais frequentes no indivíduo hemofílico, podendo ser espontâneas ou secundárias a um trauma. Os portadores de hemofilia apresentam dor persistente, que varia de intensidades moderada a intensa. Nessa população, o quadro álgico pode ocasionar a ocorrência de complicações musculoesqueléticas, como restrição dos movimentos articulares, fibrose articular, contraturas, alterações da marcha e da força muscular, hemartroses, hemorragias tissulares e artrite hemofílica (AH). O diagnóstico é feito por meio dos exames que investigam a cascata de coagulação: tempo de protrombina (TP), índice internacional normalizado (INR) e tempo de tromboplastina parcial ativada (TTPa). No caso de afetar a via intrínseca da coagulação, o TP estará normal, mas o TTPa estará alargado. Para confirmar se a deficiência é do fator IX podemos dosá-lo¨

■ Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management

Gary Benson, Günter Auerswald, Gerry Dolan et al

Blood Transfus. 2018 Nov; 16(6): 535–54

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214819/

■ Impact of prophyaxis on health-related quality of life of boys with hemofilia: na analysis of pooled data from 9 countries

Koyo Usuba, Victoria E. Price, Victor Blanchette et al

Res Pract Thromb Haemost. 2019 Jul; 3(3): 397–40

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611476/

■ Preventing lives affected by hemophilia: a mixed methods study of the views of adults with hemophilia and their families toward genetic screening

Felicity K. Boardman, Rachel Hale, Raksha Gohel, Philip J. Youn

Mol Genet Genomic Med. 2019 May; 7(5): e618

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503017/

■ Extending recombinant fator IX Fc fusion protein dosing interval to 14 or more days in patients with hemofilia B

Amy D. Shapiro, K. John Pasi, Margareth C. Ozelo et al

Res Pract Thromb Haemost. 2019 Jan; 3(1): 109–113

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332734/

■ Developing a new scoring scheme for the hemophilia Joint Health Score 2.1

Tiago Ribeiro, Audrey Abad, Brian M. Feldman

Res Pract Thromb Haemost. 2019 Jul; 3(3): 405–411

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611477/

■ Succesful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention – Case report

Kathryn E. Dane, John P. Lindsley, Michael B. Streiff et al

Res Pract Thromb Haemost. 2019 Jul; 3(3): 420–423.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611359/

■ Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: a scoping review

Jacky K. Yu, Alfonso Iorio, Andrea N. Edginton, the WAPPS co‐investigators

Res Pract Thromb Haemost. 2019 Jul; 3(3): 528–541

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611373/

■ Hemophilia trials in the twenty-first century: defining patient important outcomes

Barbara A. Konkle, Mark Skinner, Alfonso Iorio

Res Pract Thromb Haemost. 2019 Apr; 3(2): 184–192

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462740/

■ Hemofilia adquirida idiopática: um relato de caso

I N Concer, M M Felisberto, M E S Costi et al

Arquivos Catarineses de Medicina 2018, vol 47 (2)

http://www.acm.org.br/acm/seer/index.php/arquivos/article/view/239

■ Causes of death among 379 patients with hemophilia: a developing country´s report

Hassan Mansouritorghabeh, Hossein Rahimi, Seyed Tahereh Mohades, Maryam Behboud

Clin Appl Thromb Hemost. 2018 May; 24(4): 612–617

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714710/

■ Focusing in on use pharmacokinetic profiles in routine hemophilia care

Stacy E. Croteau, Michael U. Callaghan, Joanna Davis et al

Res Pract Thromb Haemost. 2018 Jul; 2(3): 607–614

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046597/

■ Performing and interpreting individual pharmacokinetic profiles in patients with hemophilia A or B: rationale and general considerations

Alfonso Iorio, Andrea N. Edginton, Victor Blanchette et al

Res Pract Thromb Haemost. 2018 Jul; 2(3): 535–548

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046594/

■ Systematic molecular analysis of hemophilia A patients from Colombia.

Yunis, Luz Karime et al.

Genet. Mol. Biol., Dec 2018, vol.41, no.4, p.750-757

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572018000500750&lng=en&nrm=iso

■ The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B

Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A. Konkle, Marshall A. Mazepa

Blood Adv. 2018 Aug 28; 2(16): 2136–2144

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113607/

■ European principles of inhibitor management in patients with haemophili

L. F. Giangrande, C. Hermans, B. O’Mahony, P. de Kleijn et al

on behalf of the European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)

Orphanet J Rare Dis. 2018; 13: 66

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921290/

■ Balance, falls, and exercise: beliefs and experiences in people with hemophilia: a qualitative study

Lorraine M. Flaherty, Jennie Schoeppe, Rebecca Kruse‐Jarres, Barbara A. Konkle

Res Pract Thromb Haemost. 2018 Jan; 2(1): 147–154

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055559/

■ A survey of characteristics and current educational needs of hemophilia treatment centers within Asia Pacific

Joyce C. M. Lam, M. Joseph John, Alison Street et al

the Asia Pacific Hemophilia Working Group (APHWG)

Res Pract Thromb Haemost. 2018 Jul; 2(3): 508–517.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046602/

■ Product type and other environmental risk factors for inhibitor development in severe hemophilia A

Flora Peyvandi, Isabella Garagiola

Res Pract Thromb Haemost. 2018 Apr; 2(2): 220–227

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055565/

■ Abordagem fisioterápica na dor e na qualidade de vida de um indivíduo com artrite hemofílica. Relato de caso

Jorge, Matheus Santos Gomes et al.

Rev. dor, Mar 2016, vol.17, no.1, p.65-6

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-00132016000100065&lng=en&nrm=iso

■ Complication of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System

R Kulkarni, R J Presley, J M Lusher et al

Haemophilia. 2017 Mar; 23(2): 207–214

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354941/

■ Gene therapy in hemophilia A: a cost-effectiveness analysis

Nicoletta Machin, Margaret V. Ragni, Kenneth J. Smith

Blood Adv. 2018 Jul 24; 2(14): 1792–1798.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058236/

■ Hemartrose subtalar, um diagnóstico raro

Rosemberg, Dov Lagus et

Rev bras.ortop 2017, vol 52 (2)

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-36162017000200228&lng=en&nrm=iso&tlng=pt ( Portuguese)

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-36162017000200228&lng=en&nrm=iso&tlng=en (English)